PPCB Propanc Biopharma, Inc. logo

PPCB Propanc Biopharma, Inc.

Healthcare
$1.76+1.73%ClosedMarket Cap: $1.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

0.16

P/S

0.00

EV/EBITDA

-0.15

DCF Value

$-16.84

FCF Yield

-267.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-151.3%

ROA

-128.1%

ROIC

-161.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 null$0.00$-6.4M$
Q2 null$0.00$-3.1M$
Q1 null$0.00$-4.8M$
Q4 null$0.00$-4.1M$

Analyst Ratings

View All

Consensus

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
ZELINGER JOSEFdirector
SellWed Aug 23
ZELINGER JOSEFdirector
SellFri Aug 20
Nathanielsz James Andrewdirector, officer: CEO/CFO
SellFri Aug 20
Nathanielsz James Andrewdirector, officer: CEO/CFO
SellFri Aug 20
Kenyon Julian Normandirector, officer: Chief Scientific Officer
SellFri Aug 20

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

AU

Exchange

Beta

3.40

Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Peers